|

Lupus Clinical Trials in Fort Worth, TX

26 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusPhase 32 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 32 mi
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy TrialPhase 42 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 42 mi
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusPhase 22 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 12 mi
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus ErythematosusPhase 213 mi
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisPhase 313 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPhase 2/313 mi
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisPhase 313 mi
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPhase 217 mi
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Phase 223 mi
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE ParticipantsPhase 1/223 mi
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusPhase 331 mi
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus—31 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/231 mi
Cutaneous Lupus Registry—31 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 231 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 231 mi
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusPhase 131 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 131 mi
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusPhase 331 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—31 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPhase 141 mi
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsPhase 145 mi
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)Phase 145 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.